癌症
癌癥
암증
CHINESE JOURNAL OF CANCER
2010年
4期
505-508
,共4页
候恺林%郝旻罡%薄隽杰%王建华
候愷林%郝旻罡%薄雋傑%王建華
후개림%학민강%박준걸%왕건화
CXCR7%趋化因子%肿瘤发生%发展
CXCR7%趨化因子%腫瘤髮生%髮展
CXCR7%추화인자%종류발생%발전
CXCR7%chemokine%tumorigenesis%progression
趋化因子属于分泌型细胞因子超家族,最早被认为前炎症性细胞因子,用来调节细胞的转运与黏附.但现今,趋化因子逐渐引起研究者的兴趣,因为越来越多的证据表明它们在肿瘤的发生和发展中发挥重要作用.CXCR7作为七次跨膜G蛋白偶联CXC亚型趋化因子受体,最近被证实与趋化因子CXCL11(I-TAC)及CXCL12(SDF-1)有高亲和力.这篇综述中,我们将着重阐述目前对于CXCR7在肿瘤牛物学过程中发挥的重要作用,涉及到肿瘤的生长、存活、黏附、侵袭、转移、血管形成及肿瘤发展等过程.目前看来,运用多肽、小分子蛋白、抗体或siRNA技术针对CXCR7的靶向措施在不久的将来有望成为肿瘤治疗的新途径.
趨化因子屬于分泌型細胞因子超傢族,最早被認為前炎癥性細胞因子,用來調節細胞的轉運與黏附.但現今,趨化因子逐漸引起研究者的興趣,因為越來越多的證據錶明它們在腫瘤的髮生和髮展中髮揮重要作用.CXCR7作為七次跨膜G蛋白偶聯CXC亞型趨化因子受體,最近被證實與趨化因子CXCL11(I-TAC)及CXCL12(SDF-1)有高親和力.這篇綜述中,我們將著重闡述目前對于CXCR7在腫瘤牛物學過程中髮揮的重要作用,涉及到腫瘤的生長、存活、黏附、侵襲、轉移、血管形成及腫瘤髮展等過程.目前看來,運用多肽、小分子蛋白、抗體或siRNA技術針對CXCR7的靶嚮措施在不久的將來有望成為腫瘤治療的新途徑.
추화인자속우분비형세포인자초가족,최조피인위전염증성세포인자,용래조절세포적전운여점부.단현금,추화인자축점인기연구자적흥취,인위월래월다적증거표명타문재종류적발생화발전중발휘중요작용.CXCR7작위칠차과막G단백우련CXC아형추화인자수체,최근피증실여추화인자CXCL11(I-TAC)급CXCL12(SDF-1)유고친화력.저편종술중,아문장착중천술목전대우CXCR7재종류우물학과정중발휘적중요작용,섭급도종류적생장、존활、점부、침습、전이、혈관형성급종류발전등과정.목전간래,운용다태、소분자단백、항체혹siRNA기술침대CXCR7적파향조시재불구적장래유망성위종류치료적신도경.
Chemokines,a family of small cytokines,were initially characterized as proinflammatory chemoattractant cytokines that regulated cell trafficking and adhesion.Today,attention focuses on chemokines because evidence shows that they play a critical role in tumor initiation,promotion,and progression.CXCR7,a seven-transmembrane G-protein-coupled CXC chemokine receptor,has recently been identified as binding with high affinity to chemokines CXCL11(I-TAC)and CXCL12(SDF-1).In this review,we highlight the current knowledge about the role of CXCR7 in the biologic processes of cancer,including cancer growth,survival,adhesion,invasion,metastasis,angiogenesis,and progression.The use of peptides,small molecules,antibodies,or small interfering RNA to target CXCR7 shows promise as new potential avenues for the treatment of cancer.